9 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
10 May 21
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
4:21pm
ongoing Phase 1b study
9-month (20 doses) chronic toxicology study completed in non-human primates with no adverse histological findings; doses exceeded
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
19 Jun 19
Regulation FD Disclosure
9:31am
thick mucus buildup in lung airways Chronic airway obstruction leads to infection and inflammation, which causes permanent tissue scarring
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Nov 19
Regulation FD Disclosure
4:01pm
airways Chronic airway obstruction leads to infection and inflammation, which causes permanent tissue scarring and respiratory failure 70,000
10-K
2019 FY
ARCT
Arcturus Therapeutics Holdings Inc
16 Mar 20
Annual report
11:09am
is challenged by an exogenous source of nitrogen such as ammonium chloride (NH4Cl) or chronic exposure to a high protein diet (“HPD”) of 53% protein … on breathing quality and will decrease the clearance of air pathogens accumulated in the mucus, causing chronic infections, chronic coughing, severe
S-4
j0pwphd6o6o4g4b
15 Mar 19
Registration of securities issued in business combination transactions
9:35pm
S-4/A
3sz16 a8fjy9
11 Apr 19
Registration of securities issued in business combination transactions (amended)
5:26pm
424B3
lqwq5
12 Apr 19
Prospectus supplement
4:39pm
- Prev
- 1
- Next